Directory
>
Srini Ramanathan
Srini Ramanathan
Chief Development Officer | Roivant Sciences
Menlo Park, California, United States
Srini Ramanathan
Summary
Srini Ramanathan is an accomplished Chief Development Officer at Roivant Sciences, where he oversees R&D operations and the establishment of new therapeutic ventures. With extensive experience in biopharmaceutics and drug development, he has played a pivotal role in the approval of numerous drugs across various therapeutic areas, including oncology and HIV. Prior to his current role, he held senior leadership positions at Horizon and Abbvie, focusing on clinical development and strategic guidance in immunology. Srini's career is marked by his ability to engage with regulatory agencies globally, ensuring successful drug approvals. He holds a Ph.D. in Pharmaceutics from Rutgers University and has a strong academic foundation in pharmacy. His leadership experience spans multiple organizations, contributing to his reputation as a key figure in the biopharmaceutical industry. Beyond his professional achievements, he is known for his collaborative approach and commitment to advancing innovative therapies.
Srini Ramanathan
Work Experience
Chief Development Officer at
Roivant Sciences
May 2022 - Present
Senior Vice President at
Amgen, Inc.
May 2021 - May 2022
Group Vice President, Development Sciences, and Site Head at
Amgen, Inc.
January 2020 - April 2021
Vice President and Site Head at
Amgen, Inc.
April 2018 - January 2020
Senior Project Leader, Immunology Development at
AbbVie
August 2016 - March 2018
Senior Director, Head of Clinical Pharmacology at
Gilead Sciences Austria
April 2003 - August 2016
Scientist, Pre-clinical Pharmacology at
ESSENTIAL THERAPEUTICS PRIVATE LIMITED
August 2001 - March 2003
Scientist at
AFFYMAX LIMITED
March 2001 - August 2001
Srini Ramanathan
Education
Rutgers University, Ph.D.
January 1997 - January 2001
Duquesne University, Master Of Science (M.S.)
January 1995 - January 1997
Birla Institute of Technology and Science, Pilani , B. Pharm.
January 1991 - January 1995
Frequently Asked Questions about Srini Ramanathan
What is Srini Ramanathan email address?
Srini Ramanathan's primary email address is ****************@roivant.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Srini Ramanathan work for?
Srini Ramanathan is a Chief Development Officer at Roivant Sciences.
Where Srini Ramanathan graduated from?
Srini Ramanathan holds a degree in Pharmaceutics from Rutgers University.
How can I directly contact Srini Ramanathan?
To contact Srini Ramanathan directly, you can use the email address ****************@roivant.com. Complete contact information is available upon registration with Muraena.
Is Srini Ramanathan an immigrant?
Yes, Srini Ramanathan is an immigrant and currently based in United States
Who is Srini Ramanathan?
Srini Ramanathan is an accomplished Chief Development Officer at Roivant Sciences, where he oversees R&D operations and the establishment of new therapeutic ventures. With extensive experience in biopharmaceutics and drug development, he has played a pivotal role in the approval of numerous drugs across various therapeutic areas, including oncology and HIV. Prior to his current role, he held senior leadership positions at Horizon and Abbvie, focusing on clinical development and strategic guidance in immunology. Srini's career is marked by his ability to engage with regulatory agencies globally, ensuring successful drug approvals. He holds a Ph.D. in Pharmaceutics from Rutgers University and has a strong academic foundation in pharmacy. His leadership experience spans multiple organizations, contributing to his reputation as a key figure in the biopharmaceutical industry. Beyond his professional achievements, he is known for his collaborative approach and commitment to advancing innovative therapies.
Srini`s contact details
****************@roivant.com
****************@gilead.com
***********@horizonpharma.com
Colleagues
Chief Communications Officer
Chief Financial Officer
Executive Director
VP, Special Projects, Office of CEO
Chief Executive Officer
Vice President, Head of CMC, Small Molecule Development
VP, Research
Board Member
Senior Vice President, Investments
Vice President, Head of CMC, Biologics and Gene Therapies